You are here

Biolidics' Covid-19 rapid test kit allowed to be marketed, sold in US

SINGAPORE-BASED cancer diagnostics company Biolidics can now distribute, market and sell its Covid-19 rapid test kits in the US, it said in a bourse filing on Monday.

The Catalist-listed firm completed its listing with the US Food and Drug Administration (FDA) on April 17. 


BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to